CSF1R and prostate carcinoma: Other CSF1R+ inhibitors include: the c-Fms inhibitor edicotinib (JNJ-40346527), in the treatment of prostate cancer (ClinicalTrials: NCT03177460); the kinase inhibitor vimseltinib, in the treatment of sarcomas, as well as TGCT (NCT04242238, NCT05059262).